Aura Biosciences Inc Total Liabilities
Aura Biosciences Inc total liabilities. Based on the latest financial reports, Aura Biosciences Inc (AURA) has total liabilities worth $30.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aura Biosciences Inc (AURA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aura Biosciences Inc (2019–2025)
Total liabilities of Aura Biosciences Inc from 2019 to 2025. This chart illustrates how Aura Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Aura Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Aura Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Zhangzhou Development Co Ltd
SHE:000753
|
China | CN¥9.03 Billion |
|
Ardmore Shipping Corporation
F:A61
|
Germany | €57.54 Million |
|
Jiangsu Olive Sensors High-Tech Co Ltd
SHE:300507
|
China | CN¥1.52 Billion |
|
Guizhou Sanli Pharmaceutical Co Ltd
SHG:603439
|
China | CN¥1.30 Billion |
|
Tiptree Inc
NASDAQ:TIPT
|
USA | $226.99 Million |
|
Innova Captab Limited
NSE:INNOVACAP
|
India | Rs-10.91 Billion |
|
SLR Investment Corp
NASDAQ:SLRC
|
USA | $1.58 Billion |
|
Mega First Corporation Bhd
KLSE:3069
|
Malaysia | RM1.55 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Aura Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Aura Biosciences Inc.
Liquidity & Leverage Metrics
Aura Biosciences Inc Total Liabilities Ratios Explained
Aura Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aura Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aura Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Aura Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $32.52 Million | +6.50% |
| 2024-12-31 | $30.53 Million | +4.47% |
| 2023-12-31 | $29.23 Million | +3.09% |
| 2022-12-31 | $28.35 Million | +267.49% |
| 2021-12-31 | $7.71 Million | +181.47% |
| 2020-12-31 | $2.74 Million | -56.44% |
| 2019-12-31 | $6.29 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more